The Zhitong Finance App learned that Swiss pharmaceutical giant RHHBY.US (RHHBY.US) plans to name its novel oral breast cancer drug Wilserdly and has registered this name in several jurisdictions. According to information from the US Patent and Trademark Office (USPTO), Genentech, an American subsidiary of Roche, submitted a trademark application on October 27 to register this name in capital letters, and also register a floral logo. Roche has also submitted applications for the same brand name to several regulators around the world, including the European Union Intellectual Property Office.

The Zhitong Finance App learned that Swiss pharmaceutical giant RHHBY.US (RHHBY.US) plans to name its novel oral breast cancer drug Wilserdly and has registered this name in several jurisdictions. According to information from the US Patent and Trademark Office (USPTO), Genentech, an American subsidiary of Roche, submitted a trademark application on October 27 to register this name in capital letters, and also register a floral logo. Roche has also submitted applications for the same brand name to several regulators around the world, including the European Union Intellectual Property Office.